Assess whether a safety signal is noise, confounding, or a real risk (51b653)

Situation

FDA Response and Labeling work in a 505(b)(2) program relying on literature plus a bridging study now turns on a safety signal is because an FAERS cluster in a demographic the trials under-enrolled put disproportionate reporting signal workbook in play. RWE evidence-strategy director should say what disproportionate reporting signal workbook proves.

Decision

RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study must choose A safety signal is noise, confounding, / A real risk using disproportionate reporting signal workbook after an FAERS cluster in a demographic the trials under-enrolled.

Hypotheses to test

• The population in disproportionate reporting signal workbook is the one an FAERS cluster in a demographic the trials under-enrolled named, so A safety signal is noise, confounding, follows for this FDA Response and Labeling file.
• The population in disproportionate reporting signal workbook is adjacent only to an FAERS cluster in a demographic the trials under-enrolled; A real risk is the honest Pharma & Life Sciences call.
• A 505(b)(2) program relying on literature plus a bridging study already contained an FAERS cluster in a demographic the trials under-enrolled before disproportionate reporting signal workbook arrived; no new FDA Response and Labeling path.
• Provenance on disproportionate reporting signal workbook after an FAERS cluster in a demographic the trials under-enrolled is broken; do not pick A safety signal is noise, confounding, or A real risk yet.

Analysis required

• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after an FAERS cluster in a demographic the trials under-enrolled.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences FDA Response and Labeling file, read disproportionate reporting signal workbook against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move a safety signal is for RWE evidence-strategy director.

Recommendation

Choose A safety signal is noise, confounding, / A real risk on this Pharma & Life Sciences / FDA Response and Labeling packet (disproportionate reporting signal workbook after an FAERS cluster in a demographic the trials under-enrolled). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after an FAERS cluster in a demographic the trials under-enrolled, then the two facts that force it, then the Monday action for RWE evidence-strategy director in a 505(b)(2) program relying on literature plus a bridging study.